Upgrade to SI Premium - Free Trial

UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral

August 10, 2021 7:01 AM
UBS analyst Esther Rajavelu downgraded Biohaven Pharmaceutical Holding (NYSE: BHVN) from Buy to Neutral with a price target of $109.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Downgrades

Next Articles